Last $11.11 USD
Change Today +0.16 / 1.46%
Volume 529.5K
IMGN On Other Exchanges
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/2/13 - $20.25
52 Week Low
07/28/14 - $10.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOGEN INC (IMGN)

immunogen inc (IMGN) Related Businessweek News

No Related Businessweek News Found

immunogen inc (IMGN) Details

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its targeted antibody payload technology. It offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. The company’s clinical-stage anticancer compounds include IMGN901, which is in Phase II clinical trials for the treatment of small-cell lung cancer; IMGN853 that is in Phase I clinical trials for ovarian cancer and non-small cell lung cancer; IMGN289, which is in active investigational new drug application stage for the treatment of head and neck cancer, and non-small cell lung cancer; and IMGN529 that is in Phase I clinical trials for non-Hodgkin lymphoma. It also develops compounds, such as SAR3419, which is in Phase II clinical trials to diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia; SAR566658 that is in Phase I clinical trials for solid tumors; SAR650984, which is in Phase I clinical trials for multiple myeloma; AMG 172 that is in Phase I clinical trials for kidney cancer; AMG 595, which is in Phase I clinical trials for glioblastoma; BAY 94-9343, that is in Phase I clinical trials for mesothelioma and ovarian cancer; and BT-062, which is in Phase I clinical trials for multiple myeloma. The company has collaborations with Sanofi; Amgen; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Roche; Novartis Institutes for BioMedical Research, Inc.; and CytomX Therapeutics. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

280 Employees
Last Reported Date: 08/29/13
Founded in 1981

immunogen inc (IMGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $502.6K
Chief Medical Officer and Vice President
Total Annual Compensation: $376.3K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $367.7K
Vice President, Secretary and General Counsel
Total Annual Compensation: $297.3K
Compensation as of Fiscal Year 2013.

immunogen inc (IMGN) Key Developments

ImmunoGen, Inc. Announces Preclinical Findings for IMGN779

ImmunoGen, Inc. disclosed for the first time preclinical data for IMGN779. The data were presented at the 19(th) Congress of the European Hematology Association (EHA) meeting in Milan, Italy. IMGN779 is a novel, CD33-targeting, DNA-alkylating ADC that is a potential treatment for acute myeloid leukemia (AML). IMGN779 is an ADC designed to selectively target and kill AML cells, including leukemic stem cells, while sparing normal cells. IMGN779 utilizes DGN462, one of the Company's new DNA-acting payload agents. In preclinical findings reported at EHA, IMGN779 demonstrated potent, targeted activity against primary AML patient cells in vitro. IMGN779 can selectively kill leukemic cells (blasts) while sparing normal hematopoietic (blood) stem cells. IMGN779 was found to be highly active against human AML xenografts in vivo, demonstrating potent and targeted activity. IMGN779 was well tolerated without delayed toxicity in animal models. IMGN779 is on track to become the Company's next wholly owned clinical-stage compound. ImmunoGen is preparing to submit the IMGN779 IND in mid-2015.

Immunogen, Inc. Announces STARLYTE Phase II Clinical Data with Sanofi's SAR3419 in Diffuse Large B-Cell Lymphoma

ImmunoGen, Inc. announced the presentation of clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a CD19-targeting ADC developed by ImmunoGen and licensed to Sanofi as part of a broader collaboration between the companies. Study investigators reported achievement of proof of concept, with 43.9% objective response rate (ORR) for the per protocol population (patients with relapsed or relapsed/refractory disease). The primary objective of the study was to assess whether single agent SAR3419 could achieve an ORR of at least 20% in this patient population using Cheson 2007 criteria. Additionally, objective responses were reported among the patients enrolled with primary refractory disease - cancer that had not responded to first-line treatment- with a 21.4% ORR. SAR3419 demonstrated promising activity against previously treated DLBCL, including disease that had not responded to first-line treatment.

ImmunoGen, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM

ImmunoGen, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Daniel M. Junius, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $11.11 USD +0.16

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bristol-Myers Squibb Co $51.12 USD +0.11
Pfizer Inc $29.26 USD -0.47
Roche Holding AG SFr.266.70 CHF +0.90
Seattle Genetics Inc $35.89 USD +0.73
View Industry Companies

Industry Analysis


Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.2x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at